Rational application of antihypertensive calcium channel blockers in renal diseases

doi:10.3877/cma.j.issn.2095-3216.2014.05.006

Abstract

Abstract:

The incidence of hypertension is high in the Chinese population. And the first cause of secondary hypertension is chronic kidney disease (CKD). To control the hypertension in CKD patients,angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) is the first choice.However, as single drug use of ACEI or ARB does not have satisfactory effect in controlling the hypertension of CKD patients, combination of other antihypertensive drugs is usually needed. Calcium channel blockers(CCB) are first-line antihypertensive drugs, but were less used in CKD patients previously due to their adverse effects. With the research progress and the development of new preparations, CCB have their certain places and advantages in treatment of hypertension patients with CKD. Rational application of CCB can improve prognosis of the kidney so as to benefit the patients.

Key words: Calcium channel blockers, Chronic kidney disease, Hypertension

Weiming Wang, Lili Xu. Rational application of antihypertensive calcium channel blockers in renal diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2014, 03(05): 251-254.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2014.05.006

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I05/251

References 17

1	中国高血压防治指南修订委员会. 中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-743.
2	Chobanian AV, Bakris GL,Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,and Treatment of High Blood Pressure: the JNC 7 report [J].JAMA,2003,289(19):2560-2572.
3	Kjeldsen SE, Erdine S, Farsang C, et al. 1999 WHO/ISH Hypertension Guidelines-highlights & ESH Update [J]. Blood Press,2003,12(3):181-182.
4	Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. J Hypertens,2013,31(7):1281-1357.
5	Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease [J]. Am J Kidney Dis, 2004, 43(5 Suppl 1): S1-S290.
6	Kidney Disease: Improving Global Outcomes ( KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease [J].Kidney Int,2012,2(Suppl 5):337-414.
7	James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee (JNC8) [J]. JAMA,2014,311(5):507-520.
8	Padwal RS, Hemmelgarn BR, Khan NA, et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1-blood pressure measurement,diagnosis and assessment of risk [J]. Can J Cardiol,2008,24(6):455-463.
9	Yuan-Nan Ke, Yu-Gang Dong, Shu-Ping Ma, et al. Improved blood pressure control with nifedipine GITS/Valsartan combination versus high-dose valsartan monotherapy in mild-to-moderate hypertensive patients from Asia: results from the ADVISE study, a randomized trial [J]. Cardiovasc Ther,2012,30(6):326-332.
10	Ruilope LM, Kirwan BA, de Brouwer S, et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial:impact of nifedipine GITS(gastrointestinal therapeutic system) and relation to outcome [J]. J Hypertens,2007,25(8):1711-1718.
11	Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients [J]. N Engl J Med,2008,359(23):2417-2428.
12	Kanaoka T, Tamura K, Wakui H, et al. L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease [J]. Int J Mol Sci,2013,14(8):16866-16881.
13	Tomino Y, Shimizu Y, Hamada C, et al. One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease [J]. J Nephrol,2011,24(6):756-763.
14	Nakamura T, Sato E, Fujiwara N, et al. Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FAB P, and inflammatory and atherosclerosis markers in earlystage chronic kidney disease [J]. Am J Med Sci, 2010, 339(2):157-163.
15	Abe M, Okada K, Maruyama N, et al. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria[J]. Hypertens Res,2011,34(2):268-273.
16	Yamamoto E, Kataoka K, Dong YF, et al. Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats [J]. J Hypertens,2010,28(6):1321-1329.
17	Swan SK, Olyaei A, Sica D. Clinical pharmacology for the nephrologist [J]. Nephrol Self Assess Program,2010,9:220-264.

[1]	Xiaoqing Tang, Ping He, You Yang, Xia Luo, Juying Zhang, Xin Yang, Jinhong Yu. Correlation of sound touch elastography combined with pulsed wave Doppler ultrasound imaging parameters with stage of early chronic kidney disease and their clinical significance [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(05): 491-499.
[2]	Yigang Wu, Yumin Pan, Shanshan Wu, Mengjuan Hu, Yiwei Wang, Jinsong Zhang, Li Qiao. Efficacy of levosimendan in the treatment of pulmonary hypertension combined with right heart failure: a meta-analysis [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(05): 385-391.
[3]	Ka Teng Chan, Meijun Du, Bing Shi, Hanyao Huang. The impact of maternal systemic diseases on the incidence of cleft lip and palate in newborns [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2024, 18(04): 262-268.
[4]	Meini Ye, Sijia Liu, Yuwei Zang, Yunjian Liu. Research progress on portal vein thrombosis in liver cirrhosis [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(05): 379-384.
[5]	Zhipeng Jiang, Keli Zhong, Shuang Chen. Prevention and management of abdominal hypertension and abdominal compartment syndrome after complex abdominal wall hernia surgery [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(06): 612-615.
[6]	Xia Luo, Baomei Wang, Shujing Li, Ying Yang. Expression of serum PCSK9 in idiopathic pulmonary hypertension and its prognostic significance [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 585-589.
[7]	Fei Wang, Zheng Chen, Decai Yu, Yajuan Cao. Minimally invasive surgical treatment of primary liver cancer with portal hypertension [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(05): 306-310.
[8]	Yidan Cai, Fang Jian, Zhiqiang Zhang, Li Chen, Shian Zhang, Lei Xia, Mei Ruan, Dongliang Li. Impact of transjugular intrahepatic portosystemic shunt on gut microbiota and liver function in patients with cirrhotic portal hypertension [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(05): 285-293.
[9]	Bokai Cheng, Guang Yang. Progress of research on application of hyperinsulinemic-euglycemic clamp technique for assessing insulin resistance in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 334-339.
[10]	Rongrong Feng, Xiaole Su, Lihua Wang. Research progress on biological markers related to complication of cardiovascular disease in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 273-278.
[11]	Junnan Guo, Hui Lin, Yilin Ren, Xi Qiao. Progress of research on the role of amino acid metabolism disturbance in the transition from AKI to CKD [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 283-287.
[12]	Minwei Zhang, Tianxu Zhai, Ziqiu Zhang, Chi Wang, Shengzhong Liu, Dechun Li. Development of a predictive nomogram model integrating abdominal CT imaging and clinical parameters for assessing the risk of elevated intra-abdominal pressure [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 549-554.
[13]	Yanping Liang, Yanrou Chen, Yunxiao Liang, Feihu Bai, Bin Wu, Xing Wang. Investigation report on endoscopic management of esophagogastric variceal bleeding in portal hypertension in Southern China [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 390-395.
[14]	Lingling Jia, Fei Teng, Jian Chang, Fu Huang, Jianping Liu. Progress in application of cardiopulmonary rehabilitation in various diseases [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(09): 859-862.
[15]	Peipei Xi, Jiajun Zhou. Progress in research of sarcopenia in patients with chronic kidney disease: pathogenesis, diagnosis, and treatment [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 491-495.

Please choose a citation manager

Content to export